A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.
A randomised trial found that adding neoadjuvant leukocyte interleukin injection with cyclophosphamide, indomethacin and zinc to standard care improved overall survival in locally advanced oral and soft palate cancers, particularly in patients with low nodal involvement and low tumour PD-L1 expression.
A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.
Read the full study at the sourceRelated CPD from Vital Pulp
Managing the Pregnant Dental Patient
Confident, evidence-based dental care from the first trimester to the postpartum period
The Recall — the month's most significant new dental research, summarised. Free.
Browse The Recall